

|                                                    |                                          |                                             |                    |                  |
|----------------------------------------------------|------------------------------------------|---------------------------------------------|--------------------|------------------|
| Patient ID<br><b>SA00119504</b>                    | Patient Name<br><b>TESTING, BILLING</b>  | Birth Date<br><b>1996-11-11</b>             | Gender<br><b>M</b> | Age<br><b>22</b> |
| Order Number<br><b>SA00119504</b>                  | Client Order Number<br><b>SA00119504</b> | Ordering Physician<br><b>CLIENT, CLIENT</b> | Report Notes       |                  |
| Account Information<br><b>C7999998 Test Client</b> |                                          | Collected<br><b>10 Apr 2019 04:00</b>       |                    |                  |

## PD-L1 (22C3) SemiQuant IHC, Manual

**Case Number CR-19-258**

### Interpretation

MCR

Lung, lower left lobe , specimen for PD-L1 immunohistochemistry studies (clone 22C3, Dako North America, Carpinteria, CA) (GB-19-6-N9):

100% tumor cells are positive for PD-L1 (membranous positivity).

PD-L1-positive immune cells cover greater than or equal to 25% of tumor area.

Interpretation: Pre-clinical studies suggest that positive PD-L1 immunohistochemistry in tumor cells may predict tumor response to therapy with immune checkpoint inhibitors. This result should not be used as the sole factor in determining treatment, as other factors (for example, tumor mutation burden, and microsatellite instability) have been also studied as predictive markers.

Fixation: This test has been validated for non-decalcified paraffin embedded tissue specimens fixed in 10% neutral buffered formalin. This assay has not been validated on tissues subjected to the decalcification process and/or use of alternative fixatives for bone/bone marrow specimens or cell blocks.

### Material Received

MCR

Report electronically signed by

MCR

A. GB-19-6: Lung, lower left lobe  
2 unstained slides

**CALEB HALL**

### Disclaimer

MCR

This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**Received:** 11 Apr 2019 08:41

**Reported:** 11 Apr 2019 08:58

### Performing Site Legend

| Code | Laboratory                                       | Address                                  | Lab Director                | CLIA Certificate |
|------|--------------------------------------------------|------------------------------------------|-----------------------------|------------------|
| MCR  | Mayo Clinic Laboratories - Rochester Main Campus | 200 First Street SW, Rochester, MN 55905 | William G. Morice M.D. Ph.D | 24D0404292       |